Latest Insider Transactions at Med Tech Acquisition Corp (MTACW)
This section provides a real-time view of insider transactions for Med Tech Acquisition Corp (MTACW). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MedTech Acquisition Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MedTech Acquisition Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 24
2025
|
Bryan F. Cox Chief of Research |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+19.36%
|
-
|
|
Nov 24
2025
|
Mary T Szela CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
425,000
+25.39%
|
-
|
|
Nov 24
2025
|
Jodi Devlin Chief of Clinical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+33.21%
|
-
|
|
Nov 24
2025
|
David Patience Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+19.7%
|
-
|
|
Nov 24
2025
|
Richard Marshak Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+34.51%
|
-
|
|
Nov 24
2025
|
Jennifer Stevens Chief Regulatory Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+28.15%
|
-
|
|
Aug 14
2025
|
David Patience Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+50.0%
|
-
|
|
May 19
2025
|
James Emmett Young Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,175
+20.97%
|
$65,875
$5.18 P/Share
|
|
May 19
2025
|
Richard Marshak Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,597
-8.71%
|
$32,985
$5.18 P/Share
|
|
May 19
2025
|
Richard Marshak Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,428
+22.06%
|
$107,140
$5.18 P/Share
|
|
May 19
2025
|
Jodi Devlin Chief of Clinical Operations |
SELL
Open market or private sale
|
Direct |
4,764
-8.28%
|
$23,820
$5.18 P/Share
|
|
May 19
2025
|
Jodi Devlin Chief of Clinical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
24,131
+29.55%
|
$120,655
$5.18 P/Share
|
|
May 19
2025
|
Bryan F. Cox Chief of Research |
SELL
Open market or private sale
|
Direct |
4,764
-3.84%
|
$23,820
$5.18 P/Share
|
|
May 19
2025
|
Bryan F. Cox Chief of Research |
BUY
Grant, award, or other acquisition
|
Direct |
15,722
+11.24%
|
$78,610
$5.18 P/Share
|
|
May 19
2025
|
Jennifer Stevens Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
8,704
-10.08%
|
$43,520
$5.18 P/Share
|
|
May 19
2025
|
Jennifer Stevens Chief Regulatory Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,455
+24.79%
|
$142,275
$5.18 P/Share
|
|
May 19
2025
|
Sean Murphy Director |
BUY
Grant, award, or other acquisition
|
Direct |
44,884
+26.58%
|
$224,420
$5.18 P/Share
|
|
Feb 18
2025
|
James Emmett Young Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,762
+28.8%
|
-
|
|
Feb 18
2025
|
Sean Murphy Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,817
+16.66%
|
-
|
|
Feb 18
2025
|
Bryan F. Cox Chief of Research |
BUY
Grant, award, or other acquisition
|
Direct |
11,450
+9.55%
|
-
|
|
Feb 18
2025
|
Jennifer Stevens Chief Regulatory Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,481
+20.01%
|
-
|
|
Feb 18
2025
|
Mary T Szela CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
21,089
+4.34%
|
-
|
|
Feb 18
2025
|
Richard Marshak Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,644
+12.35%
|
-
|
|
Feb 18
2025
|
Jodi Devlin Chief of Clinical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
5,272
+13.63%
|
-
|
|
Feb 05
2025
|
James Emmett Young Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
6,000
+16.67%
|
$30,000
$5.65 P/Share
|
|
Jan 30
2025
|
Mary T Szela CEO and President |
BUY
Open market or private purchase
|
Direct |
5,010
+1.12%
|
$25,050
$5.28 P/Share
|
|
Jan 29
2025
|
Mary T Szela CEO and President |
BUY
Open market or private purchase
|
Direct |
5,030
+1.13%
|
$25,150
$5.03 P/Share
|
|
Jan 28
2025
|
Mary T Szela CEO and President |
BUY
Open market or private purchase
|
Direct |
4,716
+1.07%
|
$23,580
$5.12 P/Share
|
|
Jan 28
2025
|
Sean Murphy Director |
BUY
Open market or private purchase
|
Indirect |
15,000
+7.05%
|
$75,000
$5.17 P/Share
|
|
Jan 27
2025
|
Mary T Szela CEO and President |
BUY
Open market or private purchase
|
Direct |
4,826
+1.11%
|
$24,130
$5.42 P/Share
|
|
Jan 27
2025
|
Mary T Szela CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+8.61%
|
-
|
|
Jan 27
2025
|
Sean Murphy Director |
BUY
Open market or private purchase
|
Indirect |
15,000
+7.59%
|
$75,000
$5.31 P/Share
|
|
Jan 27
2025
|
Sean Murphy Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+16.49%
|
-
|
|
Jan 27
2025
|
Bryan F. Cox Chief of Research |
BUY
Grant, award, or other acquisition
|
Direct |
10,625
+9.87%
|
-
|
|
Jan 27
2025
|
Jodi Devlin Chief of Clinical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
10,625
+27.42%
|
-
|
|
Jan 27
2025
|
James Emmett Young Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
24,000
+50.0%
|
$120,000
$5.4 P/Share
|
|
Jan 27
2025
|
James Emmett Young Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+36.52%
|
-
|
|
Jan 27
2025
|
Jennifer Stevens Chief Regulatory Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,625
+19.66%
|
-
|
|
Jan 27
2025
|
Richard Marshak Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+21.14%
|
-
|
|
Jan 02
2025
|
David J Matlin Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,040
+1.05%
|
-
|
|
Jan 02
2025
|
Liselotte Hyveled |
BUY
Grant, award, or other acquisition
|
Direct |
10,040
+50.0%
|
-
|
|
Dec 17
2024
|
Mats Wahlstrom Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,188
+38.1%
|
$75,564
$3.97 P/Share
|
|
Dec 17
2024
|
Equity Ab Frankenius |
BUY
Open market or private purchase
|
Direct |
62,972
+1.0%
|
$188,916
$3.97 P/Share
|
|
Dec 10
2024
|
Arjun Jj Desai Director |
SELL
Open market or private sale
|
Direct |
30,000
-10.83%
|
$90,000
$3.69 P/Share
|
|
Nov 22
2024
|
Mats Wahlstrom Director |
BUY
Open market or private purchase
|
Direct |
5,000
+24.12%
|
$20,000
$4.55 P/Share
|
|
Nov 21
2024
|
Mats Wahlstrom Director |
BUY
Open market or private purchase
|
Direct |
8,687
+44.75%
|
$34,748
$4.44 P/Share
|
|
Nov 20
2024
|
Mats Wahlstrom Director |
BUY
Open market or private purchase
|
Direct |
2,040
+50.0%
|
$8,160
$4.16 P/Share
|
|
Nov 14
2024
|
Richard Marshak Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,875
+16.77%
|
-
|
|
Oct 05
2024
|
Bryan F. Cox Chief of Research |
SELL
Open market or private sale
|
Direct |
314
-0.36%
|
$1,256
$4.44 P/Share
|
|
Sep 13
2024
|
Mary T Szela CEO and President |
BUY
Open market or private purchase
|
Direct |
7,295
+0.94%
|
$29,180
$4.92 P/Share
|